JAK2 and acquired polycythemia vera: While co-occurring mutations in patients with PV have been described in literature, further studies are needed to investigate the significance of variants identified in JAK2-negative patients classified as secondary erythrocytosis, to determine if these mutations contribute to clinical phenotype or constitute background CHIP.